Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.44 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.38 |
| ▸ | TACR2 | P21452 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.37 |
| ▸ | PDE2A | O00408 | 2/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.35 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22481120 | 0.79 | ADRB2 (0.46) | NNMT | |
| SCHEMBL2609304 | 0.76 | NNMT (0.46) | NNMTPDE10APOLBTDP1 | |
| SCHEMBL26050020 | 0.72 | ADRB2 (0.55) | TDP1 | |
| SCHEMBL22481217 | 0.72 | ADRB2 (0.57) | — | |
| SCHEMBL20113971 | 0.71 | CCR1 (0.37) | PDE2A | |
| SCHEMBL23888635 | 0.70 | CYP3A4 (0.44) | — | |
| SCHEMBL16762977 | 0.70 | LMNA (0.42) | NNMTPOLB | |
| SCHEMBL2254683 | 0.69 | NNMT (0.46) | NNMTCRHR1PDE2APOLB | |
| SCHEMBL12322217 | 0.69 | PDE10A (0.39) | NNMTCRHR1PDE10ATDP1 | |
| SCHEMBL9016286 | 0.68 | NNMT (0.50) | NNMTPDE10APDE2APDE5APDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994203-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| US-20100035874-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035874-A1 | Organic compounds | CRH, CRHR1, CRHR2 | NNMT 3988/4885CRHR1 2/4885TACR2 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.